TONMYA Drug Patent Profile

Which patents cover Tonmya, and what generic alternatives are available?

Tonmya is a drug marketed by Tonix and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries.

The generic ingredient in TONMYA is cyclobenzaprine hydrochloride. There are sixteen drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the cyclobenzaprine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tonmya

A generic version of TONMYA was approved as cyclobenzaprine hydrochloride by ACTAVIS LABS FL INC on May 3^rd, 1989.

Summary for TONMYA

International Patents:	53
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Patent Applications:	1,449
Drug Prices:	Drug price information for TONMYA
What excipients (inactive ingredients) are in TONMYA?	TONMYA excipients list
DailyMed Link:	TONMYA at DailyMed

See drug prices for TONMYA

Recent Clinical Trials for TONMYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tonix Pharmaceuticals, Inc.	Phase 3

See all TONMYA clinical trials

Pharmacology for TONMYA

Drug Class	Muscle Relaxant
Physiological Effect	Centrally-mediated Muscle Relaxation

US Patents and Regulatory Information for TONMYA

TONMYA is protected by four US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes	10,117,936		Y
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes	9,956,188		Y
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes	10,864,175		Y
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes	9,636,408		Y
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes

International Patents for TONMYA

See the table below for patents covering TONMYA around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	631152
European Patent Office	3650081
San Marino	T202000045
Poland	3650081
European Patent Office	2968992
Mexico	2015012622

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: TONMYA (Tolcapone)

Last updated: October 8, 2025

Introduction
The pharmaceutical landscape surrounding TONMYA (tolcapone), a central nervous system (CNS) agent developed primarily for the management of Parkinson’s disease, exhibits complex market dynamics influenced by regulatory shifts, therapeutic positioning, competitive landscape, and evolving patient needs. As a catechol-O-methyltransferase (COMT) inhibitor, TONMYA plays a crucial adjunctive role in Parkinson’s therapy but faces unique challenges affecting its commercial viability and long-term financial trajectory.

Overview of Toncapone (TONMYA)
Introduced in the late 1990s, TONMYA (tolcapone) was approved for patients with Parkinson’s disease experiencing motor fluctuations despite levodopa therapy. Its mechanism involves inhibiting COMT, thereby prolonging the effect of levodopa and optimizing symptom control. Despite its efficacious profile, its market penetration has been historically limited by safety concerns, primarily hepatotoxicity, which led to regulatory restrictions and impact on its sales trajectory.

Regulatory and Safety Challenges
Regulatory agencies, including the U.S. Food and Drug Administration (FDA), initially approved TONMYA with warnings regarding liver toxicity. In 2004, the FDA issued a black box warning and a Risk Evaluation and Mitigation Strategy (REMS), demanding strict liver function monitoring. This safety concern curtailed prescription rates, impacting overall market opportunity. Similar restrictions across Europe further suppressed growth potential, necessitating a reevaluation of its market positioning.

Market Dynamics

1. Therapeutic Positioning and Competition
TONMYA targets a niche segment of Parkinson’s management, primarily for patients with motor fluctuations inadequately controlled by levodopa alone. Its main competitors, entacapone (Comtan) and safinamide, offer similar benefits with balanced safety profiles. The emergence of newer drugs with improved safety margins, such as opicapone, further encroaches on TONMYA’s market share. The therapeutic landscape's evolution pushes manufacturers to emphasize combination therapies and personalized medicine, reducing reliance on drugs with notable safety restrictions.

2. Market Penetration and Adoption
The safety concerns surrounding hepatotoxicity have constrained prescribing behaviors. Physicians often prefer safer alternative COMT inhibitors, which do not require intensive liver monitoring—limiting TONMYA’s market reach. Consequently, sales volumes have remained relatively modest, with peak sales occurring shortly after approval but declining in subsequent years as safer options gained favor.

3. Regulatory Trends and Pharmacovigilance
Enhanced pharmacovigilance practices and real-world evidence have intensified scrutiny on side effects, especially hepatotoxicity. The continued emphasis on drug safety oversight can restrict or delay subsequent approvals for novel formulations or indications, affecting the drug’s long-term growth prospects.

4. Pricing and Reimbursement Landscape
Pricing strategies for TONMYA are challenged by competition and safety-related market skepticism. Reimbursement dynamics vary across regions, with payers increasingly favoring agents with proven safety profiles and favorable cost-effectiveness data. Limited reimbursement approval for TONMYA constrains revenue streams, especially in cost-sensitive markets.

Financial Trajectory

1. Revenue Trends
Initial revenue generation for TONMYA was promising, driven by unmet clinical needs and favorable efficacy data. However, safety warnings and competitive pressures resulted in a sharp decline in sales volume. According to industry reports, the drug’s annual revenue has stabilized at a fraction of its peak, primarily deriving from niche patient segments where other options are unsuitable.

2. R&D Investment and Pipeline Developments
Pharmaceutical companies may shift R&D focus toward second-generation formulations or biosimilars to mitigate safety issues. The development of safer COMT inhibitors with minimal hepatotoxicity could rejuvenate the drug’s financial prospects. However, significant investment hurdles and regulatory approval timelines pose risks to such pipelines.

3. Market Projections
Forecasting future revenue necessitates accounting for demographic trends—namely, the increasing prevalence of Parkinson’s disease in aging populations—and potential diversification of indications. The growing recognition of combination therapies and personalized medicine approaches might, in time, facilitate niche re-expansion if safety challenges are addressed robustly.

4. Strategic Partnerships and Licensing
Collaborations with biotech firms and licensing agreements could reinstate market relevance by integrating TONMYA into combination regimens or developing new formulations. Strategic alliances may also unlock funding for addressing safety concerns, thereby positively influencing the financial trajectory.

Market Outlook and Key Trends

• Emergence of Newer Agents: The advent of third-generation COMT inhibitors with improved safety profiles—such as opicapone—poses competitive threats while presenting opportunities.
• Regulatory Evolution: Increasing regulatory flexibility for drugs demonstrating enhanced safety may open pathways for reformulation or expanded indications.
• Technological Innovation: Advances in drug delivery systems and personalized medicine could enable targeted therapy, restoring interest in older agents like TONMYA.
• Patient-centric Approaches: Patient preference for safety and convenience may favor newer, safer drugs, constraining the long-term financial contribution of TONMYA unless safety concerns are mitigated.

Key Takeaways

• The initial market success of TONMYA was tempered by safety concerns, dampening its long-term growth prospects.
• Competitive pressures from safer, more convenient COMT inhibitors significantly limit TONMYA’s market share.
• Regulatory and pharmacovigilance trends are critical determinants of future market viability, especially as newer agents with better safety profiles emerge.
• Strategic R&D investments and potential reformulations could extend TONMYA’s relevance in niche patient populations.
• The long-term financial trajectory hinges on addressing safety issues, leveraging novel formulations, and participating in personalized Parkinson’s disease treatment strategies.

FAQs

1. What are the main safety concerns associated with TONMYA?
   Hepatotoxicity is the primary safety concern, leading to strict liver function monitoring and regulatory restrictions.

2. How does TONMYA compare to other COMT inhibitors?
   It offers similar efficacy but carries higher safety risks, making alternatives like entacapone and safinamide more popular.

3. Can TONMYA regain market share with new formulations?
   Potentially, if reformulated to mitigate safety issues, it could re-enter certain niche markets.

4. What is the outlook for TONMYA amid emerging Parkinson’s therapies?
   The outlook remains cautious; as newer drugs with better safety profiles dominate, TONMYA’s role may diminish unless safety concerns are addressed.

5. Are there prospects for TONMYA in personalized medicine?
   Yes, if patient stratification can identify subpopulations that tolerate the drug well, tailored therapies could offer new opportunities.

References

[1] FDA. (2004). Black Box Warning for Tolcapone.
[2] European Medicines Agency. (2015). Review of Tolcapone safety data.
[3] MarketLine. (2022). Parkinson’s Disease Therapeutics Market Analysis.
[4] IQVIA. (2021). Pharmaceutical Sales Data.
[5] GlobalData. (2022). Parkinson’s Disease Pipeline and Market Forecast.

Note: This analysis synthesizes publicly available data up to early 2023 and may not account for the latest developments.